UK's Chroma and GlaxoSmithKline Target Macrophages For Anti-Inflammatory UseI
This article was originally published in The Pink Sheet Daily
Executive Summary
In its first Big Pharma deal, Chroma Therapeutics will collaborate with GSK to develop macrophage-targeted small molecules that may provide a safer and lower-cost alternative to certain biologics